Metastatic Breast Cancer With Bone and Liver Progression After Multiple Therapies

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: Initial tumor: ER 80%, HER2 negative, Ki67 18%. Liver metastasis: ER 75%

Metastatic Site: bone, liver

After massive hepatic progression and liver failure, chemotherapy was stopped and she died on January 31, 2016.

PubMed CentralRead more →

Bilateral Breast Cancers Followed by Metastatic Disease and Long Eribulin Treatment

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: Left primary: ER 90%, HER2 FISH not amplified, Ki67 25%. Right primary: ER 90%

Metastatic Site: lung, pleura, liver, bone

After pelvic bone metastases appeared in 2017, she stopped eribulin, received pelvic radiation and remained on fulvestrant treatment.

PubMed CentralRead more →

Recurrent Breast Cancer With Liver Metastases Treated Through Multiple Chemotherapy Lines

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: Initial tumor: ER positive, HER2 0. Liver metastasis: ER 100%

Metastatic Site: liver

After liver progression following 18 cycles of eribulin, she started weekly carboplatin and remained in active treatment.

PubMed CentralRead more →

Metastatic Breast Cancer With Durable Liver and Peritoneal Response to Eribulin

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: Initial tumor: ER 90%, PgR 70%. Liver metastasis: ER 60%, HER2 1+

Metastatic Site: liver, peritoneum

While continuing eribulin beyond 34 cycles, her liver disease was stable and the peritoneal response persisted after earlier major tumor reduction.

PubMed CentralRead more →

Metastatic Breast Cancer Responding to Eribulin After Repeated Liver Progression

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: ER 100%, HER2 negative

Metastatic Site: bone, liver

Eribulin remained ongoing with repeated partial responses documented through 12 cycles and no need for dose reduction.

PubMed CentralRead more →

Stage III Breast Cancer: Jacquelyn's Patient Story

Patient Info: Jacquelyn | Stage III

Jacquelyn said her stage 3 breast cancer was in remission while hormone therapy medication continued after mastectomy, chemotherapy, and radiation.

Our Cancer StoriesRead more →

Breast Cancer: Tonya's Survivor Story

Patient Info: Tonya, Female

Tonya said she was in remission while continuing radiation therapy and hormone therapy.

Our Cancer StoriesRead more →

HER2-Positive Recurrent Breast Cancer Treated With Multiple Targeted and Local Therapies

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: 2008 recurrence: ER 80%, HER2 FISH amplified. 2011 recurrence: ER 80%

Metastatic Site: liver, skin

After 25 cycles of eribulin, treatment was still ongoing; nodal disease remained stable, while later imaging also noted new metabolic activity in the upper lung.

PubMed CentralRead more →

Breast cancer returning 21 years later as a solitary parotid metastasis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Parotid metastasis ER positive; PR positive; HER2 borderline by IHC but FISH 1.82

Metastatic Site: left parotid gland

More than 5 months after the parotid metastasis was diagnosed, the tumour had slightly decreased in size and her metastatic disease remained stable on endocrine therapy.

PubMed CentralRead more →

Breast cancer returning years later in the biceps muscle

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER positive

Metastatic Site: left biceps muscle

Her arm symptoms improved considerably after radiotherapy, and MRI 6 months later showed a significant decrease in the size of the biceps tumour.

PubMed CentralRead more →

Metastatic Breast Cancer and an Atypical Femoral Fracture During Ibandronate Treatment

Patient Info: Anonymized, female, 50s

She was living with bone-metastatic breast cancer when a suspected new femoral metastasis was instead recognized as an atypical femoral fracture during long-term ibandronate treatment.

PubMed CentralRead more →

Stage II Breast Cancer: Natalia's Survivor Story

Patient Info: Natalia | Stage II

Natalia was declared cancer-free on February 21, 2024, and continued regular follow-up while taking letrozole.

Our Cancer StoriesRead more →

Stage III Breast Cancer: Elizabeth's Survivor Story

Patient Info: Elizabeth, 40s | Stage III

Biomarkers: Cancer described as highly hormone-dependent.

Elizabeth said she was in remission and no longer required treatment after lumpectomy, chemotherapy, radiation, and an aromatase-inhibitor clinical trial.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Tasha's Patient Story

Patient Info: Tasha | Stage II

She completed surgery and radiation and is doing well as a survivor while continuing tamoxifen.

Our Cancer StoriesRead more →

Stage III Breast Cancer: Zhan's Survivor Story

Patient Info: Zhan Shen Ya Dian Na | Stage III

She reports that her breast cancer is in remission and continues hormone therapy.

Our Cancer StoriesRead more →

Metastatic Low-Grade Serous Ovarian Cancer Causing Severe Pulmonary Hypertension

Patient Info: Anonymized, female, 70+ | Stage IV

Metastatic Site: pleura, pulmonary arteries

She died on hospital day 29 after rapidly progressive pulmonary hypertension. Autopsy attributed the pulmonary hypertension to metastatic ovarian serous carcinoma with pulmonary arterial tumor emboli.

PubMed CentralRead more →

Stage IV Breast Cancer: Liu's Patient Story

Patient Info: Liu Jing | Stage IV

More than eight years after a stage 4 diagnosis, Liu Jing remained on hormone and targeted therapies and continued working, walking, and mountain hiking.

Our Cancer StoriesRead more →

Malignant Struma Ovarii With Papillary Thyroid-Type Cancer

Patient Info: Anonymized, female, 40s

Biomarkers: KRAS mutation

Radioactive iodine scans showed no local or distant disease, and she was well and symptom-free 12 months after the initial diagnosis while continuing follow-up.

PubMed CentralRead more →

Synchronous Stage IA breast cancer and Stage IIA lung adenocarcinoma: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: Breast tumor: ER/PR positive, HER2 negative. Lung tumor: KRAS/EGFR wild type, ALK rearrangement not detected.

As of April 2014, more than 2 years of follow-up showed no recurrent disease after treatment of synchronous Stage IA breast cancer and Stage IIA lung adenocarcinoma.

PubMed CentralRead more →

Mixed epithelial and mesenchymal metaplastic breast carcinoma: no recurrence 1 year after surgery and adjuvant therapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Mixed metaplastic breast cancer: epithelial part ER/PR/HER2-positive; mesenchymal part ER/PR-negative with weak HER2. Ki-67 ~20%.

As of March 2014, she was doing well with no recurrence or metastasis 1 year after modified radical mastectomy, adjuvant CEF/Taxotere chemotherapy, and tamoxifen.

PubMed CentralRead more →

Stage IV Ovarian Cancer: Bre's Patient Story

Patient Info: Bre Tipps, female, Under 40 | Stage IV

A recent CT scan showed the remaining tumors calcifying and dying during hormonal therapy, although the patient expected to need ongoing ovarian cancer treatment.

MD AndersonRead more →

Breast invasive ductal carcinoma with coexisting inflammatory myofibroblastic tumor: disease-free after mastectomy, TAC, and tamoxifen

Patient Info: Anonymized, Female, Under 40

Biomarkers: Breast cancer: ER/PR-positive with HER2 2+ and p53-positive. Separate inflammatory myofibroblastic tumor had ALK/vimentin/actin/S-100 markers.

As of August 2013, she remained disease-free 2 years after modified radical mastectomy, 6 courses of TAC chemotherapy, and tamoxifen.

PubMed CentralRead more →

Localized hormone receptor-positive breast cancer disease-free 5 years after endocrine therapy switch

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2-negative; low Ki-67; Oncotype DX 12

After lumpectomy and 36 months of adjuvant hormonal treatment, she remained disease-free at her last examination in March 2013, 5 years after diagnosis.

PubMed CentralRead more →

ER/PR-positive mucinous breast cancer treated with mastectomy and tamoxifen

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-positive; PR-positive; HER2/neu not overexpressed; no pathogenic BRCA1 or BRCA2 mutations identified; chromosome 13q34 duplication

After radical right mastectomy with nipple and areola preservation followed by tamoxifen, she showed no evidence of local recurrence or metastasis of breast cancer.

PubMed CentralRead more →